EUVIMEDEUVIMED entdecken
Crossref

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials

Rafael Grochot iD, Kroopa Joshi, Antonella Cammarota iD, Rachel Woodford iD, Gethini Sathanantham iD, Anja Williams iD, Tobias Arkenau iD, Vivek Subbiah iD, Charles Swanton, Elisa Fontana iD

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Rafael Grochot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute (SCRI), London, United Kingdom. Hauptthemen laut MEDLINE: Receptors, Fibroblast Growth Factor, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Aberrant signaling through the fibroblast growth factor receptor ( FGFR ) due to activating somatic alterations has been associated with multiple malignancies. FGFR inhibitors (FGFRi) with distinct profiles recently entered standard of care. This work summarizes the experience of a dedicated clinical trial unit with FGFRi developed in the last decade within the context of clinical trials. METHODS Demographic and clinical data were collected for patients enrolled in FGFR-targeting phase I to II trials conducted at Sarah Cannon Research Institute, United Kingdom between January 2012 and August 2023. RESULTS Fifty-four patients across seven trials were identified: 50% male; median age 55 years. An FGFR alteration was present in 81% of cases; rearrangements, amplifications, and mutations were present in 59%, 43%, and 9.1% of the cases, respectively, with coexisting alterations in 27%. The most frequent primary tumors were cholangiocarcinomas (31%), urothelial (15%), and colorectal (15%); 85% of the patients were FGFRi-naïve. The most common adverse events (AEs) were hyperphosphatemia (42%), dry mouth (35%), fatigue (24%), mucositis (24%), nail changes (22%), and palmar-plantar erythrodysesthesia (20%), with significant differences between pan-FGFRi and FGFR-2i. The rate of G3 AEs was 22%; no G4-5 events were observed. The median time on treatment was 3.5 months (0.2-72.8). Higher disease control rate was observed in the presence of any FGFR alteration, compared with all-comers (odds ratio [OR], 7; P = .0226). The objective response rate was 38%, 25%, and 25% in patients with gene rearrangements, amplification, and mutations, respectively. The median duration of response was 2.3 months (1.6-7.7). After a median follow-up time of 20 months (95% CI, 12.9 to 71.8), median progression-free survival (mPFS) was 3.2 months (95% CI, 1.9 to 4.6) and median overall survival was 13 months (95% CI, 6.4 to 19.6). PFS was significantly different by response, FGFR status, and tumor type. Patients who experienced a G2-3 AE were more likely to achieve a response (OR, 5.24; P = .0256). CONCLUSION FGFRi are effective treatment strategies for patients with advanced solid tumors harboring FGFR alterations, with manageable toxicities in most patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Fibroblast Growth FactorNeoplasmsAntineoplastic AgentsHumansMaleMiddle AgedFemaleAgedAdultAged, 80 and overClinical Trials, Phase I as Topic

Substanzen

Receptors, Fibroblast Growth FactorAntineoplastic Agents

Autor:innen und Institutionen

  • Sarah Cannon Research Institute (SCRI), London, United Kingdom.
  • Humanitas University, Milan, Italy.
  • University College London, London, United Kingdom.
  • Ellipses Pharma, London, United Kingdom.
  • Sarah Cannon Research Institute, Nashville, TN.
  • Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.

ORCID-Profile: Rafael Grochot, Antonella Cammarota, Rachel Woodford, Gethini Sathanantham, Anja Williams, Tobias Arkenau, Vivek Subbiah, Elisa Fontana

Zitieren

APA

Grochot, R., Joshi, K., Cammarota, A., Woodford, R., Sathanantham, G., Williams, A., Arkenau, T., Subbiah, V., Swanton, C., & Fontana, E. (2025). Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials. JCO Precision Oncology. https://doi.org/10.1200/po-24-00896

Vancouver

Grochot R, Joshi K, Cammarota A, Woodford R, Sathanantham G, Williams A, et al. Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials. JCO Precision Oncology. 2025. doi:10.1200/po-24-00896

BibTeX
@article{Grochot2025,
  author = {Grochot, Rafael and Joshi, Kroopa and Cammarota, Antonella and Woodford, Rachel and Sathanantham, Gethini and Williams, Anja and Arkenau, Tobias and Subbiah, Vivek and Swanton, Charles and Fontana, Elisa},
  title = {Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00896}
}
Kostenlos starten →